| |
| |
|
| Insider
Information: |
Formela Jean Francois |
| Relationship: |
|
| City: |
Waltham |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
13 |
|
| Direct
Shares |
7,291 |
|
|
Indirect Shares
|
24,762,873 |
|
|
| Direct
Value |
$164,048 |
|
|
|
Indirect Value
|
$273,373,794 |
|
|
| Total
Shares |
24,770,164 |
|
|
| Total
Value |
$273,537,842 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
4
|
|
Stock
price went up :
|
0
|
4
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
4.0
|
| Percentage
Gain/Loss : |
0.0%
|
 179.9%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Decode Genetics Inc |
DCGN |
Director |
2003-09-09 |
0 |
2003-12-11 |
0 |
Premium* |
|
|
Exelixis Inc |
EXEL |
Director |
2003-11-13 |
0 |
2005-09-07 |
584,519 |
Premium* |
|
|
Nxstage Medical, Inc. |
NXTM |
Director, 10% Owner |
|
0 |
2006-05-26 |
2,592,126 |
Premium* |
|
|
Sgx Pharmaceuticals, Inc. |
SGXP |
Director, 10% Owner |
2006-02-01 |
0 |
2006-02-06 |
2,485,068 |
Premium* |
|
|
Achillion Pharmaceuticals Inc |
ACHN |
Director, 10% Owner |
2006-10-31 |
0 |
2006-10-31 |
1,968,670 |
Premium* |
|
|
Nuvelo Inc |
ABIO |
Director, 10% Owner |
|
0 |
2012-10-22 |
1,579,542 |
Premium* |
|
|
Horizon Pharma, Inc. |
HZNP |
Director, 10% Owner |
|
0 |
2011-08-02 |
5,393,178 |
Premium* |
|
|
Egalet Corp |
EGLT |
Director, 10% Owner |
|
0 |
2014-02-11 |
2,460,949 |
Premium* |
|
|
Intellia Therapeutics, Inc. |
NTLA |
Director |
2022-06-14 |
7,291 |
2021-06-28 |
10,000 |
Premium* |
|
|
Spero Therapeutics Inc |
SPRO |
Director |
2017-11-06 |
0 |
2017-11-06 |
2,408,128 |
Premium* |
|
|
Translate Bio, Inc. |
TBIO |
Director |
2018-07-02 |
0 |
2021-09-14 |
0 |
Premium* |
|
|
Ikena Oncology, Inc. |
IKNA |
Director |
|
0 |
2021-12-14 |
4,143,544 |
Premium* |
|
|
Korro Bio |
KRRO |
|
2023-11-03 |
0 |
2024-04-22 |
1,137,149 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| KRRO |
Korro Bio |
|
– • – |
2024-04-22 |
4 |
A |
$56.00 |
$999,992 |
I/I |
17,857 |
195,074 |
0 |
- |
|
| KRRO |
Korro Bio |
|
– • – |
2023-11-03 |
4 |
A |
$0.00 |
$0 |
I/I |
1,119,292 |
177,217 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
Director |
– • – |
2022-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
5,197 |
7,291 |
0 |
- |
|
| IKNA |
Ikena Oncology, Inc. |
Director |
– • – |
2021-12-14 |
4 |
S |
$14.00 |
$83,426 |
I/I |
(5,959) |
1,241,935 |
0 |
- |
|
| IKNA |
Ikena Oncology, Inc. |
Director |
– • – |
2021-12-13 |
4 |
S |
$14.64 |
$121,951 |
I/I |
(8,330) |
1,247,894 |
0 |
- |
|
| IKNA |
Ikena Oncology, Inc. |
Director |
– • – |
2021-12-10 |
4 |
S |
$15.03 |
$180,195 |
I/I |
(11,989) |
1,256,224 |
0 |
- |
|
| TBIO |
Translate Bio, Inc. |
Director |
– • – |
2021-09-14 |
4 |
AS |
$38.00 |
$78,092,394 |
I/I |
(2,055,063) |
0 |
0 |
% |
|
| NTLA |
Intellia Therapeutics, In... |
Director |
– • – |
2021-06-28 |
4 |
AS |
$127.02 |
$73,448,879 |
I/I |
(553,376) |
10,000 |
0 |
% |
|
| NTLA |
Intellia Therapeutics, In... |
Director |
– • – |
2021-06-23 |
4 |
A |
$0.00 |
$0 |
D/D |
2,094 |
2,094 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
Director |
– • – |
2021-06-14 |
4 |
AS |
$85.92 |
$14,921,294 |
I/I |
(170,779) |
563,376 |
0 |
% |
|
| NTLA |
Intellia Therapeutics, In... |
Director |
– • – |
2021-06-11 |
4 |
AS |
$85.18 |
$2,637,480 |
I/I |
(30,946) |
734,155 |
0 |
% |
|
| NTLA |
Intellia Therapeutics, In... |
Director |
– • – |
2021-04-29 |
4 |
AS |
$85.43 |
$385,546 |
I/I |
(4,513) |
765,101 |
0 |
% |
|
| NTLA |
Intellia Therapeutics, In... |
Director |
– • – |
2021-04-28 |
4 |
AS |
$85.40 |
$11,287,893 |
I/I |
(131,926) |
769,614 |
0 |
% |
|
| NTLA |
Intellia Therapeutics, In... |
Director |
– • – |
2021-04-27 |
4 |
AS |
$85.39 |
$18,125,992 |
I/I |
(210,230) |
901,540 |
0 |
% |
|
| NTLA |
Intellia Therapeutics, In... |
Director |
– • – |
2021-04-26 |
4 |
AS |
$84.93 |
$68,454 |
I/I |
(806) |
1,111,770 |
0 |
% |
|
| NTLA |
Intellia Therapeutics, In... |
Director |
– • – |
2021-04-05 |
4 |
AS |
$84.98 |
$67,984 |
I/I |
(800) |
1,112,576 |
0 |
% |
|
| IKNA |
Ikena Oncology, Inc. |
Director |
– • – |
2021-03-30 |
4 |
A |
$0.00 |
$0 |
I/I |
4,750,361 |
749,634 |
0 |
- |
|
| IKNA |
Ikena Oncology, Inc. |
Director |
– • – |
2021-03-30 |
4 |
B |
$16.00 |
$2,000,000 |
I/I |
125,000 |
874,634 |
2.1 |
- |
|
| IKNA |
Ikena Oncology, Inc. |
Director |
– • – |
2021-03-25 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
169,095 |
|
- |
|
| NTLA |
Intellia Therapeutics, In... |
Director |
– • – |
2021-02-26 |
4 |
S |
$60.29 |
$30,262,716 |
I/I |
(501,945) |
1,113,376 |
0 |
% |
|
| TBIO |
Translate Bio, Inc. |
Director |
– • – |
2020-12-22 |
4 |
AS |
$25.04 |
$2,069,870 |
I/I |
(82,565) |
43,940 |
0 |
% |
|
| TBIO |
Translate Bio, Inc. |
Director |
– • – |
2020-12-21 |
4 |
AS |
$25.50 |
$1,441,928 |
I/I |
(56,536) |
126,505 |
0 |
% |
|
| TBIO |
Translate Bio, Inc. |
Director |
– • – |
2020-08-27 |
4 |
S |
$14.38 |
$145,217 |
I/I |
(10,097) |
3,833,122 |
0 |
% |
|
| TBIO |
Translate Bio, Inc. |
Director |
– • – |
2020-08-26 |
4 |
S |
$14.80 |
$656,746 |
I/I |
(44,381) |
3,843,219 |
0 |
% |
|
| TBIO |
Translate Bio, Inc. |
Director |
– • – |
2020-08-25 |
4 |
S |
$15.00 |
$516,160 |
I/I |
(34,410) |
3,887,600 |
0 |
% |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
